Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dr. Stephen Spielberg to Host Prominent Professionals at DIA EuroMeeting 2013

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
DIA Europe’s 25th Annual EuroMeeting to be held in Amsterdam from 4-6 March, 2013.

Dr. Stephen Spielberg, M.D., Ph.D., Editor-in-Chief of DIA’s peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS), will be meeting high-profile industry experts from around the world at DIA Europe’s 25th Annual EuroMeeting in Amsterdam from 4-6 March, 2013.

Dr. Spielberg will welcome EuroMeeting 2013 participants at the DIA’s exhibition booth on Monday 4 March.

Then, on 6 March, a host of prominent industry experts, including representatives from the European Medicines Agency (EMA) and the Directorate General for Health and Consumer Affairs (DG SANCO), will be invited to a meet and greet breakfast and a TIRS Editorial lunch.

Dr. Spielberg said: “I am greatly looking forward to welcoming participants to the EuroMeeting 2013 in Amsterdam. This year promises to be an insightful event with 110 comprehensive sessions.”

More than 300 high-profile speakers, moderators, and panelists from around the world are set to attend EuroMeeting 2013, substantiating the meeting’s claim to being the most important event in the medicines development calendar.

The meeting will feature 200 exhibitors and bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centres, health ministries, and delegates from patient organizations to share knowledge focusing on better public health protection, greater transparency of processes, and the rational use of medicinal products.

For more information about the event visit www.diahome.org/EM2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!